TY - JOUR
T1 - Imaging, Treatment Options, Patient Selection, and Outcome Considerations for Patients With Bicuspid Aortic Valve Disease
AU - Ahmad, Yousif
AU - Agarwal, Vratika
AU - Williams, Matthew L.
AU - Wang, Dee Dee
AU - Reardon, Michael J.
AU - Cavalcante, João L.
AU - Makkar, Raj
AU - Forrest, John K.
N1 - Funding Information:
Dr Wang has served as a consultant to Edwards Lifesciences, Abbott, NeoChord, and Boston Scientific and has received research grant support from Boston Scientific assigned to her employer, the Henry Ford Health System. Dr Reardon served as national surgical principal investigator on SURTAVI, Evolut Low-Risk, Reprise III, Acurate, Portico NG, and Vantage and received research support from Medtronic, Boston Scientific, Abbott Medical, and Gore. Dr Cavalvante has received consulting fees from Boston Scientific and Abbott Vascular and has received research grant support from Circle Cardiovascular Imaging, Edwards Lifesciences, Medtronic, Boston Scientific, and Abbott Vascular. He has been a speaker for Medtronic, Circle Cardiovascular Imaging, and Siemens Healthineers. Dr Makkar has received research grants from Edwards Lifesciences, Abbott, Medtronic, and Boston Scientific and has served as national principal investigator for Portico (Abbott) and Acurate (Boston Scientific) US investigation device exemption trials. In addition, he has received personal proctoring fees from Edwards Lifesciences and travels support from Edwards Lifesciences, Abbott, and Boston Scientific. Dr Forrest is a consultant for Edwards Lifesciences and Medtronic and receives grant support from Edwards Lifesciences and Medtronic. Drs Ahmad, Agarwal, and Williams reported no financial interests. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The research reported has adhered to the relevant ethical guidelines.
Funding Information:
Dr Wang has served as a consultant to Edwards Lifesciences, Abbott, NeoChord, and Boston Scientific and has received research grant support from Boston Scientific assigned to her employer, the Henry Ford Health System. Dr Reardon served as national surgical principal investigator on SURTAVI, Evolut Low-Risk, Reprise III, Acurate, Portico NG, and Vantage and received research support from Medtronic, Boston Scientific, Abbott Medical, and Gore. Dr Cavalvante has received consulting fees from Boston Scientific and Abbott Vascular and has received research grant support from Circle Cardiovascular Imaging, Edwards Lifesciences, Medtronic, Boston Scientific, and Abbott Vascular. He has been a speaker for Medtronic, Circle Cardiovascular Imaging, and Siemens Healthineers. Dr Makkar has received research grants from Edwards Lifesciences, Abbott, Medtronic, and Boston Scientific and has served as national principal investigator for Portico (Abbott) and Acurate (Boston Scientific) US investigation device exemption trials. In addition, he has received personal proctoring fees from Edwards Lifesciences and travels support from Edwards Lifesciences, Abbott, and Boston Scientific. Dr Forrest is a consultant for Edwards Lifesciences and Medtronic and receives grant support from Edwards Lifesciences and Medtronic. Drs Ahmad, Agarwal, and Williams reported no financial interests.
Publisher Copyright:
© 2022 The Authors
PY - 2022/11/1
Y1 - 2022/11/1
N2 - Transcatheter aortic valve replacement has emerged as a safe and effective alternative to surgical aortic valve replacement for patients with severe symptomatic aortic stenosis across the spectrum of surgical risks based on a series of foundational randomized clinical trials. Of note, patients with bicuspid aortic valve (BAV) disease were excluded from all these pivotal randomized trials, leaving a significant knowledge gap because BAVs are commonly encountered in patients referred for aortic valve surgery or intervention. In this comprehensive review, we aim to provide heart teams with a detailed insight into how to approach patients with BAV disease, focusing on imaging and characterization of bicuspid valves, an overview of surgical approaches, and an understanding of the current data behind the role of transcatheter aortic valve replacement for patients with BAV disease.
AB - Transcatheter aortic valve replacement has emerged as a safe and effective alternative to surgical aortic valve replacement for patients with severe symptomatic aortic stenosis across the spectrum of surgical risks based on a series of foundational randomized clinical trials. Of note, patients with bicuspid aortic valve (BAV) disease were excluded from all these pivotal randomized trials, leaving a significant knowledge gap because BAVs are commonly encountered in patients referred for aortic valve surgery or intervention. In this comprehensive review, we aim to provide heart teams with a detailed insight into how to approach patients with BAV disease, focusing on imaging and characterization of bicuspid valves, an overview of surgical approaches, and an understanding of the current data behind the role of transcatheter aortic valve replacement for patients with BAV disease.
KW - bicuspid aortic valve
KW - severe aortic stenosis
KW - surgical aortic valve replacement
KW - transcatheter aortic valve replacement
UR - http://www.scopus.com/inward/record.url?scp=85161914142&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85161914142&partnerID=8YFLogxK
U2 - 10.1016/j.jscai.2022.100506
DO - 10.1016/j.jscai.2022.100506
M3 - Review article
AN - SCOPUS:85161914142
SN - 2772-9303
VL - 1
JO - Journal of the Society for Cardiovascular Angiography and Interventions
JF - Journal of the Society for Cardiovascular Angiography and Interventions
IS - 6
M1 - 100506
ER -